Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992862 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Paddock Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00992862: Completed Phase 1 study, sponsored by Paddock Laboratories.
NCT00992862 is a Phase 1 study that has completed, run by Paddock Laboratories. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00992862, a Phase 1 study, has completed, sponsored by Paddock Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.
Interventions
- DRUG Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.
- DRUG Univasc® 15mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 1 |
What the finished NCT00992862 record still lists
NCT00992862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc. is the first listed.
NCT00992862 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00992862 about?
NCT00992862 is a clinical study titled "A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.
What is the current status of trial NCT00992862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants.
What interventions are being tested in trial NCT00992862?
The interventions under investigation include: Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc. (DRUG), Univasc® 15mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00992862?
This trial is sponsored by Paddock Laboratories, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00992862's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors